Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Eddingpharm Gains China Rights for Cancer Drug from Syndax

publication date: Sep 4, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eddingpharm has in-licensed China rights to a clinical-stage cancer treatment from Syndax Pharma of Massachusetts. Entinostat is an oral epigenetic drug that was designed to reverse resistance to targeted oncology therapies. Eddingpharm will develop the drug in China, a process that includes participating in Syndax’s global Phase III trials of the drug. It will also have manufacturing rights to entinostat. Syndax will receive milestone and royalty payments from Eddingpharm for entinostat, though specific amounts were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners